Ligand Pharmaceuticals Incorporated research snapshot
LGND AI stock analysis currently reads Ligand Pharmaceuticals Incorporated as a high-margin biopharma royalty aggregator that completed the roughly $739 million all-cash acquisition of XOMA Royalty on July 14, 2026, more than doubling its royalty portfolio to more than 200 commercial and development-stage assets. At the August 3, 2026 cutoff, LGND traded near $286.27 with a market capitalization around $5.74 billion, down about 12% from its July 8 all-time high of $326.63 as the market digests the integration and waits for the August 6 Q2 earnings report. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$286.27
Market cap
$5.74 billion
AI score
71 / 100
Rating
Royalty aggregator with doubled portfolio, still premium valuation
Trend status
Pullback from all-time high within a strong longer-term uptrend
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Ligand now owns royalty interests in more than 200 biopharmaceutical assets across immunology, oncology, infectious disease, CNS, and kidney disease after closing the XOMA Royalty acquisition, generating high-margin recurring revenue with only 47 employees. | High |
| Moat | The moat comes from Captisol and NITRICIL formulation platforms, contractual royalty structures, and a more diversified portfolio of 200+ partnered assets that creates switching costs for licensees. | Medium |
| Management | CEO Todd Davis and the team executed a disciplined shift toward royalty aggregation, capped by the accretive XOMA Royalty deal. Integration execution and the $625M convertible note financing now carry the main management risks. | Medium |
| Financial trend | TTM revenue reached about $274.48 million with a profit margin near 56%. Q1 2026 showed a net loss of $13.34M driven by deal-related charges, while prior quarters showed strong profitability and milestone-driven revenue. | Medium-high |
| Valuation | At about 37x trailing EPS and 21.5x sales, LGND trades at a premium to the biotech and pharma sector medians. A cash-flow DCF near $404 suggests discount, but earnings-based multiples still look rich. | Medium |
| Technical trend | The stock pulled back roughly 12% from its all-time high of $326.63 set on July 8, 2026, to near $286. YTD return is about 51% and the 1-year return about 116%, so the longer-term trend stays up. | Medium |
| Risk level | Main risks are XOMA integration execution, revenue lumpiness, royalty concentration, convertible note dilution, partner-dependent cash flows, small-cap volatility, and valuation risk at about 37x earnings. | Medium-high |
| AI confidence | High for descriptive research, quote snapshots, and verified calculations. Lower for future price outcomes because LGND is driven by milestone payments, licensing deals, XOMA accretion, and partner drug performance that are hard to forecast. | High data confidence |
| Investment certainty | Low-medium certainty. LGND has a differentiated model, strong margins, and momentum, but the current price embeds high expectations and the margin of safety remains limited. | Low-medium |
LGND AI stock forecast
The LGND AI stock forecast uses scenario math around the $286.27 quote and $7.68 TTM EPS. The three-year framework produced a bullish area near $320 to $360, a base area near $235 to $265, and a bearish area near $145 to $190, depending on XOMA accretion, EPS growth, partner drug performance, and assigned multiples.
$320 to $360
More likely if the XOMA Royalty integration delivers the projected $0.50 and $1.50 per share accretion for 2026 and 2027 adjusted EPS, new licensing deals continue, partner drug sales grow, and the market awards a 25-30x forward multiple on 12-15% EPS growth.
$235 to $265
More likely if EPS compounds around 8-10% annually, XOMA integration is smooth but unspectacular, milestone payments stay lumpy, and the market applies a 20-24x multiple closer to the specialty pharma peer range.
$145 to $190
More likely if integration problems emerge, key partner drugs face clinical or regulatory setbacks, milestone revenue misses estimates, convertible note dilution hits EPS, or the market compresses the multiple below 18x.
LGND AI technical analysis
LGND AI technical analysis shows a pullback within a strong longer-term uptrend. The stock set an all-time high of $326.63 on July 8, 2026, then fell about 12% to near $286 at the August 3, 2026 cutoff. TradingView technicals turned sell-biased in the very short term while the 1-week and 1-month ratings still lean buy.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $286.27 | Quote snapshot from Yahoo Finance at the August 3, 2026 cutoff, used for market cap math. Google Finance showed $283.77 at a similar time. |
| All-time high | $326.63 | Set on July 8, 2026, the reference point for the current pullback. |
| Near support | $280 to $290 | The immediate trading zone near round numbers where the stock is currently basing after the pullback. |
| Stronger support | $255 to $265 | The late-June base before the surge to the all-time high, a psychological zone on deeper pullbacks. |
| Key resistance | $300 to $310 | The post-breakdown congestion area. Reclaiming it would improve the short-term setup. |
| All-time-high resistance | $326 to $330 | The July 8 high zone. A clean breakout above $330 would open the path higher. |
| 52-week low | $131.67 | Set in July 2025, the stock has more than doubled from this level. |
| Momentum | Pullback within uptrend | YTD return of 51.41% and 1-year return of about 116%, but 1-month return of -10.41% and 5-day return of -3.77% show the near-term pullback. |
| Volume | About 355,000 to 503,000 daily shares | Average volume is modest for a small-cap stock and varies by source. |
| Volatility | Moderate-high small-cap biotech volatility | Expect larger moves around the August 6 Q2 earnings report, licensing deal announcements, clinical data, and XOMA integration news. |
| Invalidation | Close below $255, then $240 | A decisive break below $255 would weaken the longer-term bullish structure. A break below $240 would suggest a deeper correction. |
LGND AI trading strategy
The LGND AI trading strategy is a rules-based research framework for a small-cap biopharma royalty aggregator in a pullback within a longer-term uptrend, ahead of an earnings event and a recent acquisition. It is not personal advice and should be paired with live quotes, filings, and event-risk monitoring.
Watch for LGND to reclaim the $300 to $310 resistance zone and later clear the $326.63 all-time high with above-average volume and positive catalyst news such as the August 6 Q2 results or XOMA integration milestones.
A failure to reclaim $300 or a close below $265 should invalidate the trend-following setup.
If LGND pulls back toward $255 to $265 on normal volatility without a fundamental thesis break, compare entry with Q2 results, XOMA accretion progress, cash position, and recent deal flow.
Do not average down without a defined loss limit because small-cap biotech stocks can gap down on adverse partner-product or integration news.
Track Q2 2026 earnings on August 6, the December 8 Investor Day with an updated five-year outlook, XOMA Royalty integration, quarterly revenue mix between royalties and milestones, cash position, and convertible note impact.
Reduce exposure if integration costs rise, the company needs additional equity, or a key partner drug faces a clinical or regulatory setback.
Investment research summary
Ligand converts biopharmaceutical royalty rights, licensing fees, and milestone payments into high-margin recurring revenue with a lean team of about 47 employees. The July 14, 2026 close of the roughly $739 million XOMA Royalty acquisition more than doubled its portfolio to more than 200 royalty assets.
The moat is strongest where Captisol and NITRICIL formulation technology create technical switching costs for licensees and where contractual royalty streams provide recurring revenue independent of Ligand operational execution. It narrows if partner drugs face competition, patent expiry, or clinical failure.
The thesis fails if XOMA Royalty integration underperforms its projected EPS accretion, revenue becomes too dependent on a few partner products, milestone payments stay lumpy, convertible note dilution compresses EPS, or the small-cap structure amplifies any negative surprise into severe multiple compression.
Management has executed a disciplined shift toward royalty aggregation, capped by the XOMA Royalty deal expected to add about $0.50 and $1.50 to 2026 and 2027 adjusted EPS. Execution and financing risk now sit with integration and an updated five-year outlook promised at the December 8 Investor Day.
The biopharma industry benefits from aging populations, rising healthcare spending, and continued innovation. The royalty aggregation model is a proven approach that reduces operational risk, but it depends on partner execution and the ability to keep funding high-value programs.
At about $286, LGND trades around 37x trailing earnings and 21.5x sales. A Simply Wall St DCF put intrinsic value near $404, suggesting a discount on cash flow, while earnings multiples look rich versus peers. Margin of safety is thin until growth is proven.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| LGND price | $286.27 (Yahoo); $283.77 (Google Finance) | Yahoo Finance and Google Finance quote snapshots | August 3, 2026 |
| Market capitalization | $5.74 billion, verified as $286.27 x 20.04 million shares | financial_rigor.py market cap verification | August 3, 2026 |
| TTM revenue | $274.48 million (consensus of sources) | Yahoo Finance and Google Finance cross-check | August 3, 2026 |
| TTM net income | $153.56 million (Yahoo). Q1 2026 net income was -$13.34 million due to deal-related charges. | Yahoo Finance cross-check | August 3, 2026 |
| EPS (TTM) | $7.68 (Yahoo); $7.42 (Google Finance) | Yahoo Finance and Google Finance | August 3, 2026 |
| Cash and equivalents | $779.4 million (most recent quarter) | Yahoo Finance key statistics | August 3, 2026 |
| Debt-to-equity | 45.32% | Yahoo Finance | August 3, 2026 |
| Levered free cash flow (TTM) | $142.11 million | Yahoo Finance | August 3, 2026 |
| Valuation check | 37.3x trailing P/E, 32.3x forward P/E, 21.5x price/sales, 5.8x price/book | financial_rigor.py valuation verification and Yahoo Finance | August 3, 2026 |
| Analyst consensus | Buy (8 analysts, all Buy). Yahoo average target $323.30, Google average $342.43, high $388.00 (BofA), low $247-$289 | Yahoo Finance and Google Finance analyst ratings | August 3, 2026 |
| Shares outstanding | 20.04 million | Yahoo Finance and Google Finance | August 3, 2026 |
| XOMA Royalty acquisition | Completed July 14, 2026, total equity value about $739 million at $39.00 per share cash, expanding the portfolio to more than 200 royalty assets | GlobeNewswire via Yahoo Finance | July 14, 2026 |
| Convertible notes offering | $625 million of 0% convertible senior notes due 2031, priced in June 2026 | GlobeNewswire via Yahoo Finance | June 2026 |
| Upcoming earnings | Q2 2026 results scheduled for August 6, 2026 | GlobeNewswire via Yahoo Finance | August 3, 2026 |
This LGND AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of future return. Forecast ranges are scenarios based on available filings, quote snapshots, technical data, and third-party sources as of the stated cutoff date. They may be wrong, incomplete, or outdated after new earnings, the August 6 Q2 report, XOMA Royalty integration updates, licensing deals, clinical data, convertible note developments, market moves, or macro conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
